IDEXX Laboratories, Inc. (IDXX)

Healthcare
Diagnostics & Research
United States
Yahoo Finance  •  Trading View  •  Company site
Price
$639.15
▲ 2.24 (0.35%)
Market Cap
$51,135,004,672
Shares: 82,467,000
P/E
38.40
P/B: 21.37
ROE
55.65%
Current Ratio: 1.31
Fundamentals Score
69 (NEUTRAL)

Company Overview

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It offers in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology, and coagulation analyzers; and SNAP rapid assays test kits. The company also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, it offers diagnostic tests, services, and related instrumentation for manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Headquarters: One IDEXX Drive, Westbrook, ME, 04092, United States  |  Employees: 11000  |  Website: idexx.com
Key Contacts
IR / Phone: 207 556 0300
Exchange: NMS
Industry: Diagnostics & Research
Quick Financial Snapshot
Revenue$3,897,504,000
Net Income$887,867,000
Free Cash Flow$798,079,000
Book Value / Share$19.34

Balance Sheet & Liquidity

Total Liabilities$1,698,130,000
Total Equity$1,595,313,000
Debt / Equity0.62
Current Ratio1.31
Interest Coverage36.16
Working Capital$331,981,000

Valuation Metrics

Core multiples and valuation signals — useful to compare vs peers.

P/E (TTM)38.40
Industry P/EN/A
Forward P/E53.44
P/B21.37
Price / Sales8.75
P / FCF42.72
EV / EBITDA27.27
Graham Number$68.46
DCF (placeholder)
Notes: red items typically indicate expensive multiples relative to fundamentals. Use the "Compare with industry" tool for context.

EPS (Annual)

Financial Performance

Revenue vs Net Income

Free Cash Flow (annual)

Profitability & Efficiency

Gross Margin 61.04%
Operating Margin 28.95%
Net Margin 22.78%
ROIC 33.87%
Asset Turnover 1.18

Automated Fundamental Signals (Score: 69)

Passed
  • EPS shows upward trend
  • EPS CAGR 12.10%
  • Price CAGR 24.24%
  • ROIC 33.9%
  • Gross Margin 61.0%
  • Debt/Equity ratio
  • Operating Margin 29.0%
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
Failed
  • P/FCF 42.72
  • P/B Ratio 21.37
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)

Price Chart (Candlestick)

Technical Analysis (Score: 85)

RSI (14)53.33
SMA 50640.24
SMA 200513.56
MACD-0.70
Signal BULLISH
RSI 53.3, SMA trend bullish, momentum 33.7%.

Governance & Management

Governance scores: Audit: 4 | Board: 1 | Compensation: 5 | Shareholder Rights: 4
Executive Team
NameTitle
Mr. Jonathan J. Mazelsky President, CEO & Director (1961)
Mr. Michael J. Lane Executive VP and GM Global Reference Laboratories, Diagnostic Solutions & Information Technology (1968)
Dr. Nimrata Khatra Hunt P.E., Ph.D. Executive Vice President of Global Strategy & Commercial (1968)
Dr. Martin Smith Ph.D. Executive Vice President of Global Operations and R&D (1968)
Mr. Andrew Emerson Executive VP, CFO & Treasurer (1983)
Mr. Bob Asmann Senior Vice President of Global Operations (—)
Ms. Sharon E. Underberg J.D. Executive VP, General Counsel, & Corporate Secretary (1961)
Ms. Julie Godon Senior VP & Global Marketing Officer (—)
Governance data last updated: 10/1/2025

Latest News

What to Expect From IDEXX Laboratories’ Q3 2025 Earnings Report
Yahoo • Oct 15, 2025 • Neutral

IDEXX Laboratories is set to announce its third-quarter results next month, with analysts forecasting robust double-digit growth in earnings.

Edwards Lifesciences: Inflection Incoming, But When?
SeekingAlpha • Oct 14, 2025 • Neutral

Get insights on Edwards Lifesciences Corporation: market leadership, growth trends, and valuation analysis. Click for more on EW stock prospects.

IDEXX Laboratories Inc. stock outperforms competitors on strong trading day
MarketWatch • Oct 13, 2025 • Positive

IDEXX Laboratories Inc. stock outperforms competitors on strong trading day

← Back